The Technical Analyst
NGM Biopharmaceuticals [NGM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
NGM Biopharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.00% $1.540
America/New_York / 4 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 128.53 mill |
| EPS: | -1.730 |
| P/E: | -0.890 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 83.46 mill |
| Avg Daily Volume: | 0.952 mill |
| RATING 2024-04-04 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.890 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.890 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.613 (-60.22%) $-0.927 |
| Date: 2024-04-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.457 - 1.623 ( +/- 5.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Tcg Opportunity Iii Gp, Llc | Buy | 1 000 | Common Stock |
| 2024-04-05 | Tcg Opportunity Iii Gp, Llc | Sell | 44 000 | Common Stock |
| 2024-04-05 | Column Group Gp, Lp | Buy | 1 000 | Common Stock |
| 2024-04-05 | Column Group Gp, Lp | Sell | 44 000 | Common Stock |
| 2024-04-05 | Column Group L P | Buy | 1 000 | Common Stock |
| INSIDER POWER |
|---|
| -56.26 |
| Last 100 transactions |
| Buy: 3 241 050 | Sell: 9 885 031 |
Forecast:
16:00 - $1.550
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.550
Forecast 2: 16:00 - $1.550
Forecast 3: 16:00 - $1.550
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.540 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 0.952 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NGM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $1.431 | N/A | Active |
|---|
NGM
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-05 09:19:00 - Press Release
Ngm Bio Announces Closing Of Tender Offer
San francisco, april 05, 2024 (globe newswire) -- ngm biopharmaceuticals, inc. (“ngm bio”) (nasdaq: ngm), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that atlas neon parent, inc. (“parent”), an affiliate of the column group, lp (“tcg”), through its wholly-owned subsidiary atlas neon merger sub, inc. (“merger sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of ngm bio not held by affiliates of tcg and certain other stockholders at a price per share of $1.55 in cash (the “offer price”).
2024-03-21 03:30:00 - Press Release
Important Investor Alert: The Schall Law Firm Announces It Is Investigating Claims Against Ngm Biopharmaceuticals, Inc. And Encourages Investors To Contact The Firm
Los angeles, ca / accesswire / march 21, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in ngm biopharmaceuticals, inc. ("ngm bio" or "the company") (nasdaq:ngm) for potential breaches of fiduciary duty on the part of its directors and management. the investigation focuses on determining if the ngm bio board breached its fiduciary duties to shareholders.
2024-03-20 07:00:00 - Press Release
Investor Action Notice: The Schall Law Firm Announces It Is Investigating Claims Against Ngm Biopharmaceuticals, Inc. And Encourages Investors To Contact The Firm
Los angeles, ca / accesswire / march 20, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in ngm biopharmaceuticals, inc. ("ngm bio" or "the company") (nasdaq:ngm) for potential breaches of fiduciary duty on the part of its directors and management. the investigation focuses on determining if the ngm bio board breached its fiduciary duties to shareholders.
2024-03-19 17:30:00 - Press Release
Ngm Bio To Present Two Posters Highlighting Clinical Data From The Ongoing Phase 1/2 Clinical Trial Of Ngm707, A Dual Ilt2/ilt4 Antagonist Antibody Product Candidate, At Aacr 2024 Annual Meeting
South san francisco, calif., march 19, 2024 (globe newswire) -- ngm biopharmaceuticals, inc. (ngm bio) (nasdaq: ngm), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing phase 1/2 clinical trial of ngm707, a dual ilt2/ilt4 antagonist antibody product candidate, have been selected for presentation at the american association for cancer research (aacr) annual meeting, being held april 5-10, 2024 in san diego, ca.
2024-03-19 03:30:00 - Press Release
Important Investor Alert: The Schall Law Firm Announces It Is Investigating Claims Against Ngm Biopharmaceuticals, Inc. And Encourages Investors To Contact The Firm
Los angeles, ca / accesswire / march 19, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in ngm biopharmaceuticals, inc. ("ngm bio" or "the company") (nasdaq:ngm) for potential breaches of fiduciary duty on the part of its directors and management. the investigation focuses on determining if the ngm bio board breached its fiduciary duties to shareholders.
Latest News
2024-03-19 17:30:00 - GlobeNewsWire
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.
2024-03-11 18:31:06 - Zacks Investment Research
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
2024-03-07 10:16:12 - Zacks Investment Research
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2023-11-02 18:47:13 - Zacks Investment Research
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.59 per share a year ago.
2023-08-03 18:46:37 - Zacks Investment Research
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
2023-05-25 09:00:00 - GlobeNewsWire
NGM Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.
2023-02-28 20:20:05 - Zacks Investment Research
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-03 20:20:37 - Zacks Investment Research
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-03 11:22:15 - Zacks Investment Research
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-10-20 10:59:05 - PennyStocks
3 Best Penny Stocks To Buy Before November According To Insiders
Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.